Regulatory Convergence for Pharmaceuticals in East/Central Africa
Convergence of regulatory requirements has many benefits, such as ensuring favorable marketing conditions to support early access to medicinal products, promoting competition and efficiency, and reducing unnecessary duplication of clinical testing. Achieving convergence of pharmaceutical regulations in Africa would also assist continental efforts for the control of a growing cross-border market of substandard and falsified medicines in circulation in the continent. This workshop will bring together pharmaceutical companies, U.S. and African government representatives and multilateral partners to discuss best practices and identify practical steps needed to strengthen regulatory oversight of pharmaceuticals and improve market access for these essential medicines in the region.
Click here for the flyer.
- Ms. Hala Abu Ghazalah, Regional head AFME, Regulatory Policy, Pfizer
- Amb. Dr. Fatuma Adan, Head of Mission, Intergovernmental Authority on Development (IGAD)
- Ms. Angeline Achoka, Senior Regulatory Affairs Manage, AstraZeneca
- Dr. Knyenje Gakombe, Chair, Kenya Healthcare Federation
- Dr. John Mwangi, Head of Regulatory Affairs, Bayer
- Mr. James Nyamosi, Associate Partner, Workforce Productivity Centre
- Dr. Winnie, Ng’ang’a-Mwangi, Chairperson, Kenya Association of Pharmaceutical Industry (KAPI)
- Dr. Christopher Odero, Regulatory Policies and Intelligence, Roche
- Mr. Johnpaul Omollo, Senior Policy and Advocacy Officer, PATH
- Mr. Evans Sagwa, Director Eastern & Southern Africa, U.S. Pharmacopeia (USP)